Philadelphia, Pa. (October 1, 2013) – A telestroke service increases the rate of effective tissue plasminogen activator (tPA) therapy for patients with acute ischemic stroke treated at community hospitals, according to a report in the October issue of Neurosurgery, official journal of the Congress of Neurological SurgeonsCongress of Neurological Surgeons. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.
Other studies in the October Neurosurgery find that known gene variants don't affect the size of brain aneurysms and that surgery for a brain defect called Chiari malformation I (CMI) improves outcomes important to patients.
Remote Stroke Service Increases tPA Use at Community Hospitals
Dr. Stavropoula Tjoumakaris and colleagues of Thomas Jefferson University Hospital evaluated the effects of a telestroke network including 28 community hospitals in the Philadelphia area. In the network, stroke specialists used "remote presence" technology to consult on the care of stroke patients seen at hospitals that didn't have a specialized stroke unit. The study evaluated the rate of appropriate treatment with tPA—an effective "clot-busting" drug that can be given only within the first few hours after initial stroke symptoms.
Over 18 months, the service provided nearly 1,650 remote stroke consultations; the average time from request to telemedicine response was just 12 minutes. About 14 percent of patients received tPA—including nearly all of those who could be treated in the appropriate time window. By comparison, national data suggest that only three to five percent of patients with ischemic stroke receive tPA.
About 80 percent of network hospitals increased their use of tPA for acute ischemic stroke. The percentage of patients transferred to a specialized stroke center decreased as well—possibly because patients began to improve at their original hospital. The researchers conclude, "The results support the implementation of telestroke networks for wider access to stroke expertise in underserved regions."
Gene Variants Show Little Effect on Aneurysm Size
Dr. Rachel Kleinloog and colleagues of Medical Center Utrecht, The Netherlands, looked for evidence of the effects of gene variants on the size of brain aneurysms. The study included two groups totaling nearly 1,000 patients with ruptured aneurysms of blood vessels supplying the brain.
However, none of seven gene variants previously linked to aneurysms was significantly related to aneurysm size. Average aneurysm size was 7.6 millimeters for patients with a higher genetic risk score versus 7.7 millimeters for those with a lower score. The researchers note that the known variants account for no more than five percent of the genetic risk of aneurysm—other genetic factors affecting aneurysm size and rupture risk may yet be identified.
Patient-Reported Outcomes after Surgery for CMI
Dr. Scott L. Parker and colleagues of Vanderbilt University Medical Center analyzed patient-reported outcomes in 50 adult patients undergoing an operation called suboccipital decompression for CMI. Chiari malformation I is a brain defect that causes part of the lower brain to be pushed down into the spinal canal. Patients with CMI often have no symptoms until adolescence or adulthood.
Three-fourths of patients had improvement in severe headaches—a major symptom of CMI. Surgery also provided good improvements in abnormal cerebrospinal fluid flow (syringes) and neurological abnormalities. Three-fourths of employed patients were able to return to work.
The study provides important information on key outcomes important to patients, with new insights into the expected benefits of surgery for CMI. "This patient-centered assessment suggests that suboccipital decompression for CMI in adults is an effective treatment strategy," The researchers conclude.
About Neurosurgery
Neurosurgery, the Official Journal of the Congress of Neurological SurgeonsCongress of Neurological Surgeons, is your most complete window to the contemporary field of neurosurgery. Members of the Congress and non-member subscribers receive 3,000 pages per year packed with the very latest science, technology, and medicine, not to mention full-text online access to the world's most complete, up-to-the-minute neurosurgery resource. For professionals aware of the rapid pace of developments in the field, Neurosurgery is nothing short of indispensable.
About Wolters Kluwer Health Wolters Kluwer Health is a leading global provider of information, business intelligence and point-of-care solutions for the healthcare industry. Serving more than 150 countries and territories worldwide, Wolters Kluwer Health's customers include professionals, institutions and students in medicine, nursing, allied health and pharmacy. Major brands include Health Language®, Lexicomp®, Lippincott Williams & Wilkins, Medicom®, Medknow, Ovid®, Pharmacy OneSource®, ProVation® Medical, and UpToDate®.
Wolters Kluwer Health is part of Wolters Kluwer, a market-leading global information services company. Wolters Kluwer had 2012 annual revenues of €3.6 billion ($4.6 billion), employs approximately 19,000 people worldwide, and maintains operations in over 40 countries across Europe, North America, Asia Pacific, and Latin America. Follow our official Twitter handle: @WKHealth.
Journal
Neurosurgery